<DOC>
	<DOCNO>NCT01024686</DOCNO>
	<brief_summary>The purpose study assess safety tolerability escalate dos genetically attenuate parasite malaria vaccine ( p52-/p36- GAP vaccine ) healthy malaria-naive adult . The study also assess preliminary efficacy p52-/p36- GAP vaccine follow primary experimental challenge P. falciparum sporozoite . Lastly , study assess immunogenicity p52-/p36- GAP malaria-na√Øve healthy adult preliminary efficacy p52-/p36- GAP vaccine follow primary experimental re-challenge P. falciparum sporozoite .</brief_summary>
	<brief_title>Phase 1/2a Trial Pf GAP p52-/p36- Sporozoite Malaria Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male nonpregnant , nonlactating female 18 50 year age ( inclusive ) time enrollment Free significant health problem establish medical history , laboratory assessment clinical examination enter study Volunteers must low cardiac risk factor accord NHANES I criteria nonsignificant electrocardiogram ( EKG ) determine expert consultant cardiologist Available participate duration study Reproductive status : female participant must : reproductive potential : i.e . surgically , medically physiologically sterile , engage sexual activity could lead pregnancy : agrees consistently use contraception 2 month last protocol visit . Contraception define use 1 follow method : condom ( male female ) without spermicide diaphragm cervical cap spermicide intrauterine device ( IUD ) hormonal contraception If volunteer indicate he/she active duty military ( DCT signin page intake form ) , approval supervisor Division Director use Statement Supervisor 's Approval Form must sign file prior receipt test product Written informed consent must obtain subject screening procedure Prior entry study , subject must score least 80 % correct 10 question multiplechoice quiz assess understand study . Prior receipt investigational malaria vaccine Use investigational nonregistered drug vaccine study vaccine within 30 day precede first dose study vaccine , plan use study period Administration vaccine within 30 day first study vaccination Any past history malaria Planned travel malarious area study period Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection A family history congenital hereditary immunodeficiency Moderate high 5year cardiovascular risk determine NHANES 1 model An abnormal 12lead electrocardiogram ( EKG ) suggestive cardiac disease determine clinician Seropositive HIV , Hepatitis C virus ( antibody HCV ) and/or HBsAg Hepatomegaly , right upper quadrant abdominal pain tenderness History splenectomy Chronic active neurologic disease include seizure disorder chronic migraine headache History psoriasis porphyria Acute chronic , clinically significant pulmonary , cardiovascular , ocular , hematologic , hepatic renal functional abnormality , determine physical examination abnormal baseline laboratory screen test medical history review Administration chronic ( defined 14 day ) immunosuppressant immunemodifying drug within six month vaccination . For corticosteroid , define prednisone , equivalent , 0.5 mg/kg/day . Inhaled topical steroid allow . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration study period Current chronic use medication know cause drug reaction chloroquine and/or atovaquone/proguanil cimetidine metoclopramide . Current chronic use use within one month prior enrollment antibiotic antimalarial effect tetracycline acne , sulfa drug recurrent urinary tract infection , etc . Pregnant lactate female Female willing intend become pregnant study two ( 2 ) month study completion Any history allergic reaction anaphylaxis previous vaccination History severe reaction mosquito bite . Inability make followup visit complete diary card Suspected know current alcohol abuse/drug abuse obtain history physical examination Any significant finding opinion investigator would increase risk adverse outcome participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>